AZD 5069

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AZD 5069 (AZD5069) 是一种有效、选择性、缓慢可逆且可口服生物利用的 CXCR2 拮抗剂，可抑制 CXCL8 与 CXCR2 的结合，pIC50 为 9.1。

AZD 5069 (AZD5069)?is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1; weakly inhibits CXCL8 binding to CXCR1 with pIC50<7, and no affinity for CCR2 and CCR5; inhibits neutrophil chemotaxis with pA2 of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1; demonstrates potential activity in acute LPS-induced lung inflammation models.Pancreatic Cancer Phase 2 Clinical.

——

——

AZD5069 | AZD-5069

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

Cancer

Pancreatic Cancer

878385-84-3

476.51

C18H22F2N4O5S2

>98% (HPLC)

DMSO : 90 mg/mL 188.87 mM

O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O

N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide

(-20℃)

With Ice Pack

≥ 2 years